
    
      This phase II study is designed to evaluate the efficacy and safety of pegylated liposomal
      doxorubicin (PLD) combined with ifosfamide (IFO) for the first-line treatment of patients
      with advanced or metastatic soft tissue sarcoma (STS).
    
  